Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

Authors Jean-Pierre Armand, Vincent Ribrag, Jean-Luc Harrousseau, Lauren Abrey

Published 15 May 2007 Volume 2007:3(2) Pages 213—224

Jean-Pierre Armand1, Vincent Ribrag1, Jean-Luc Harrousseau1, Lauren Abrey2

1Institut Gustave-Roussy, Desmolins, Villejuif Cedex, France; 2Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Abstract: Procarbazine HCl is a ‘nonclassical’ oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin’s lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin’s lymphoma and primary central nervous system lymphoma. Procarbazine is a prodrug that undergoes metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and protein synthesis. Early use of procarbazine in combination with mechlorethamine, vincristine, and prednisone (MOPP) was effective in the treatment of advanced Hodgkin’s lymphoma, but late toxic effects such as secondary cancer and infertility led to its replacement by other regimens. However, its recent reintroduction in the dose-intensified BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded very promising findings. Procarbazine alone, or more commonly combined in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas. The most common side effects of procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system effects. In conclusion, the use of procarbazine in combination with other drugs means that it remains a major anticancer drug in the management of Hodgkin’s lymphoma and gliomas.

Keywords: procarbazine, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphoma, brain tumor, glioma

Download Article [PDF] 

Readers of this article also read:

In vitro cytotoxicity of the ternary PAMAM G3–pyridoxal–biotin bioconjugate

Uram Ł, Szuster M, Gargasz K, Filipowicz A, Wałajtys-Rode E, Wołowiec S

International Journal of Nanomedicine 2013, 8:4707-4720

Published Date: 11 December 2013


Rapidis A, Sarlis N, Lefebvre J-L, et al

Therapeutics and Clinical Risk Management 2008, 4:1381-1381

Published Date: 5 December 2008

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Zinelabidine Abouelfadel, E David Crawford

Therapeutics and Clinical Risk Management 2008, 4:513-526

Published Date: 11 April 2008

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, Jeffrey M Jacobson

Therapeutics and Clinical Risk Management 2008, 4:473-485

Published Date: 11 April 2008

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007